Table 2. Change in Metabolic Measures per Week of Treatment by Randomized Group in Phase 1.

Metabolic Measures	Randomized Group	N 1	Rate of Change 2	SE	P Value 3
Weight (pounds)	Olanzapine	99	0.12	0.06	0.032
	Quetiapine	94	0.14	0.06	0.019
	Risperidone	85	0.10	0.06	0.07
BMI (kg/m2)	Olanzapine	97	0.02	0.01	0.039
	Quetiapine	92	0.03	0.01	0.014
	Risperidone	84	0.02	0.01	0.07
Waist circumference (inches)	Olanzapine	96	0.07	0.02	0.004
	Quetiapine	92	0.01	0.03	0.61
	Risperidone	80	0.01	0.03	0.72
Systolic BP (mmHg)	Olanzapine	99	−0.01	0.12	0.95
	Quetiapine	94	0.17	0.12	0.16
	Risperidone	85	−0.11	0.12	0.36
Diastolic BP (mmHg)	Olanzapine	99	−0.05	0.07	0.43
	Quetiapine	94	0.09	0.07	0.23
	Risperidone	85	−0.13	0.07	0.06
HDL cholesterol (mg/dL)	Olanzapine	99	−0.19	0.07	0.004
	Quetiapine	93	−0.09	0.07	0.19
	Risperidone	83	0.03	0.07	0.68
Triglyceride (mg/dL)	Olanzapine	75	0.42	0.59	0.48
	Quetiapine	73	0.55	0.63	0.38
	Risperidone	67	0.43	0.65	0.51
Glucose (mg/dL)	Olanzapine	77	0.10	0.11	0.37
	Quetiapine	72	0.12	0.12	0.32
	Risperidone	67	0.24	0.13	0.06

¹All available follow-up visits in phase 1 were included for each subject in the longitudinal data analysis. Analysis on triglyceride and glucose were performed among fasting samples and patients whose glucose < 100mg/dL with unknown fasting status

²Adjusted for age at randomization and gender

³P-value obtained from mixed effects model evaluating the weekly rate of change in each second-generation antipsychotic treatment group relative to the placebo group